Latest Breaking News On - Corrected visual acuity - Page 1 : comparemela.com

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) - Rezolute (NASDAQ:RZLT)

Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual

Tirtht patelChristen baglaneasAraj agrawalArshad khananiQuan dong nguyenStanford university school of medicineHead of ophthalmological clinical development at rezoluteRezolute incSecurities exchangeReno school of medicineByers eye instituteUniversity of nevadaStanford university schoolScientific advisoryClinical professorReno school

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease.

Christen baglaneasQuan dong nguyenAraj agrawalArshad khananiTirtht patelReno school of medicineSecurities exchangeUniversity of nevadaRezolute incStanford university school of medicineHead of ophthalmological clinical development at rezoluteByers eye instituteStanford university schoolScientific advisoryClinical professorReno school

Rezolute Inc (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402

Rezolute Inc (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Araj agrawalQuan dong nguyenArshad khananiChristen baglaneasTirtht patelStanford university school of medicineByers eye instituteUniversity of nevadaSecurities exchangeRezolute incReno school of medicineHead of ophthalmological clinical development at rezoluteStanford university schoolScientific advisoryClinical professorReno school

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoSteve pakolaDana cormackChris brinzeyMark barakatPeter kaiserAmerican academy of ophthalmologyTechnology platformCleveland clinic lerner college of medicineSecurities exchangeExchange commissionCorporate communicationsTechnology platform licenseesOphthalmology researchClearside biomedical inc

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2.

United statesSan franciscoSteve pakolaPeter kaiserChris brinzeyDana cormackMark barakatAmerican academy of ophthalmologyTechnology platformExchange commissionCole eye instituteCorporate communicationsTechnology platform licenseesClearside biomedical incOphthalmology researchSecurities exchange